LONDON (Reuters) - Britain's healthcare cost watchdog said it was unable to recommend use of Bristol-Myers Squibb's schizophrenia drug Abilify in children aged 15 to 17 and has asked for more information on its effectiveness. (Source: Reuters: Health) Read from Source
